1. Home
  2. AVLN vs WLTH Comparison

AVLN vs WLTH Comparison

Compare AVLN & WLTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$28.73

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Wealthfront Corporation Common Stock

WLTH

Wealthfront Corporation Common Stock

N/A

Current Price

$9.41

Market Cap

1.3B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AVLN
WLTH
Founded
N/A
2008
Country
United States
United States
Employees
N/A
391
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
AVLN
WLTH
Price
$28.73
$9.41
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$12.86
AVG Volume (30 Days)
258.9K
1.0M
Earning Date
N/A
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.58
Revenue Next Year
N/A
$23.43
P/E Ratio
N/A
$10.57
Revenue Growth
N/A
N/A
52 Week Low
$24.90
$7.20
52 Week High
$33.32
$14.12

Technical Indicators

Market Signals
Indicator
AVLN
WLTH
Relative Strength Index (RSI) 43.91 50.46
Support Level $26.68 $8.65
Resistance Level $29.59 $11.28
Average True Range (ATR) 1.99 0.28
MACD 0.19 0.05
Stochastic Oscillator 61.44 61.73

Price Performance

Historical Comparison
AVLN
WLTH

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About WLTH Wealthfront Corporation Common Stock

Wealthfront Corp is a product-driven technology company that built a financial solutions platform for digital natives. The platform is designed to address the needs of the wealth builders within these generations. Its business model is designed to optimize for clients' success. The focus on delivering fully automated services results in being one of the lowest cost producers in each category in which participate. The group generates revenue from cash management and investment advisory products. Cash management revenue is earned from fees received for the delivery of cash management services, including the cash sweep program.

Share on Social Networks: